Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
-8.19 (-3.40%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 230.12 - 238.21
52 week 42.41 - 497.00
Open 237.29
Vol / Avg. 0.00/428,127.00
Mkt cap 4.91B
P/E     -
Div/yield     -
EPS -16.30
Shares 21.15M
Beta     -
Inst. own 60%
Aug 13, 2014
Intercept Pharmaceuticals Inc at Wedbush Securities Life Sciences Conference - 10:20AM EDT - Add to calendar
Aug 11, 2014
Q2 2014 Intercept Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jul 17, 2014
Intercept Pharmaceuticals Inc Annual Shareholders Meeting
Jun 25, 2014
Intercept Pharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 23, 2014
Intercept Pharmaceuticals Inc at Citi NASH Workshop
Jun 12, 2014
Intercept Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 3, 2014
Intercept Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 14, 2014
Intercept Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Intercept Pharmaceuticals Inc at Deutsche Bank Healthcare Conference
May 7, 2014
Q1 2014 Intercept Pharmaceuticals Inc Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -63558.42% -4180.51%
Operating margin -7690.04% -2432.84%
EBITD margin - -2426.33%
Return on average assets -707.36% -51.65%
Return on average equity - -91.41%
Employees 50 -
CDP Score - -


SUITE 505, 450 W. 15TH STREET
NEW YORK, NY 10011
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.

Officers and directors

Jonathan T. Silverstein J.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Barbara G. Duncan Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 57
Bio & Compensation  - Reuters
Luciano Adorini M.D. Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Strategy Officer
Age: 41
Bio & Compensation  - Reuters
Daniel P. Regan Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Paolo Fundaro Independent Director
Age: 40
Bio & Compensation  - Reuters
Sanj K. Patel Independent Director
Age: 44
Bio & Compensation  - Reuters